There were no deaths considered related to the study treatment.In conclusion, tirzepatide demonstrated superior efficacy compared to titrated insulin degludec in individuals with type 2 diabetes, as evidenced by greater reductions in HbA1c and body weight at week 52 and a lower risk of hypoglycemia
Do not adjust your medication yourself
Phase 3 trials sometimes produce slightly different results than Phase 2 due to differences in patient selection, study duration, and statistical methodology
This important hormone has been mimicked in certain medications now used to treat diabetes and obesity, offering promising results
Haekyu Kim: Conceptualization, Investigation, Methodology, Writing original draft, Writing review & editing
Unfortunately, despite significant advances in anti-glycemic therapies, macrovascular complications are still the most common cause of death in T2D patients [5]